A thermally responsive Tat-elastin-like polypeptide fusion protein induces membrane leakage, apoptosis, and cell death in human breast cancer cells

Journal of Drug Targeting

Volumn 15, Issue 9, 2007, Pages 611-622

  Massodi, Iqbal ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Drug delivery; Elastin like polypeptide; Hyperthermia; MCF 7; Thermally responsive; Tumor

Indexed keywords

HYBRID PROTEIN; TAT ELASTIN LIKE POLYPEPTIDE FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL DEATH; CELL MEMBRANE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; ERYTHROCYTE; HEAT TOLERANCE; HEMOLYSIS; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; ELASTIN; GENE PRODUCTS, TAT; HUMANS; L-LACTATE DEHYDROGENASE; RECOMBINANT FUSION PROTEINS; TEMPERATURE;

EID: 35648978993     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701502780     Document Type: Article

References (45)

1. Bidwell 3rd, GL and Raucher, D. (2005) Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther, 4:7, pp. 1076-1085.
2. Bidwell 3rd, GL and Fokt, I. (2006) Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol
3. Chilkoti, A. and Dreher, MR (2002) Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev, 54:5, pp. 613-630.
4. Moore, V Del Gaizo and Payne, RM (2004) Transactivator of transcription fusion protein transduction causes membrane inversion. J Biol Chem, 279:31, pp. 32541-32544.
5. Dewhirst, MW and Prosnitz, L. (1997) Hyperthermic treatment of malignant diseases: Current status and a view toward the future. Semin Oncol, 24:6, pp. 616-625.
6. Duncan, R. (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov, 2:5, pp. 347-360.
7. El-Sayed, ME and Hoffman, AS (2005) Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin Biol Ther, 5:1, pp. 23-32.
8. Falk, MH and Issels, RD (2001) Hyperthermia in oncology. Int J Hyperthermia, 17:1, pp. 1-18.
9. Feyerabend, T. and Steeves, R. (1997) Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res, 17:4, pp. 2895-2897.
10. Hallbrink, M. and Floren, A. (2001) Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta, 1515:2, pp. 101-109.
11. Hed, J. and Hallden, G. (1987) The use of fluorescence quenching in flow cytofluorometry to measure the attachment and ingestion phases in phagocytosis in peripheral blood without prior cell separation. J Immunol Methods, 101:1, pp. 119-125.
12. Hildebrandt, B. and Wust, P. (2002) The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol, 43:1, pp. 33-56.
13. Issels, RD (1995) Regional hyperthermia combined with systemic chemotherapy of locally advanced sarcomas: Preclinical aspects and clinical results. Recent Results Cancer Res, 138, pp. 81-90.
14. Jung, HJ and Park, Y. (2006) Biological activity of Tat (47-58) peptide on human pathogenic fungi. Biochem Biophys Res Commun, 345:1, pp. 222-228.
15. Jurisic, V. and Spuzic, I. (1999) A comparison of the NK cell cytotoxicity with effects of TNF-alpha against K-562 cells, determined by LDH release assay. Cancer Lett, 138:1, pp. 67-72.
16. Kopecek, J. and Kopeckova, P. (2000) HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action. Eur J Pharm Biopharm, 50:1, pp. 61-81.
17. Kurokawa, H. and Nishio, K. (1999) Alteration of caspase-3 (CPP32/Yama/ apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep, 6:1, pp. 33-37.
18. Leuschner, C. and Hansel, W. (2004) Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des, 10:19, pp. 2299-2310.
19. Liang, Y. and Yan, C. (2001) Apoptosis in the absence of caspase 3. Oncogene, 20:45, pp. 6570-6578.
20. Lindgren, M. and Hallbrink, M. (2000) Cell-penetrating peptides. Trends Pharmacol Sci, 21:3, pp. 99-103.
21. Liu, W. and Dreher, MR (2006) Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release, 116:2, pp. 170-178.
22. Massodi, I. and Bidwell 3rd, GL (2005) Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release, 108:2, pp. 396-408.
23. Meyer, DE and Chilkoti, A. (1999) Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol, 17:11, pp. 1112-1115.
24. Meyer, DE and Kong, GA (2001) Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res, 61:4, pp. 1548-1554.
25. Meyer, DE and Shin, BC (2001) Drug targeting using thermally responsive polymers and local hyperthermia. J Control Release, 74:1, pp. 213-224.
26. Mori, S. and Watanabe, W. (1995) A colorimetric LDH assay for the titration of infectivity and the evaluation of anti-viral activity against ortho and paramyxoviruses. Tohoku J Exp Med, 177:4, pp. 315-325.
27. Nuutila, J. and Lilius, EM (2005) Flow cytometric quantitative determination of ingestion by phagocytes needs the distinguishing of overlapping populations of binding and ingesting cells. Cytometry A, 65:2, pp. 93-102.
28. Raucher, D. and Chilkoti, A. (2001) Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. Cancer Res, 61:19, pp. 7163-7170.
29. Riedl, SJ and Shi, Y. (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol, 5:11, pp. 897-907.
30. Rinne, J. and Albarran, B. (2007) Lization of novel non-viral vector TAT-streptavidin into human cells. BMC Biotechnol, 7:1, p. 1.
31. Saar, K. and Lindgren, M. (2005) Cell-penetrating peptides: A comparative membrane toxicity study. Anal Biochem, 345:1, pp. 55-65.
32. Sabatier, JM and Vives, E. (1991) Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol, 65:2, pp. 961-967.
33. Scheller, A. and Oehlke, J. (1999) Structural requirements for cellular uptake of alpha-helical amphipathic peptides. J Pept Sci, 5:4, pp. 185-194.
34. Takahashi, I. and Emi, Y. (2002) Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery, 131:1, pp. S78-S84.
35. Tatham, AS and Shewry, PR (2000) Elastomeric proteins: Biological roles, structures and mechanisms. Trends Biochem Sci, 25:11, pp. 567-571.
36. Temsamani, J. and Vidal, P. (2004) The use of cell-penetrating peptides for drug delivery. Drug Discov Today, 9:23, pp. 1012-1019.
37. Torchilin, VP (1998) Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul, 15:1, pp. 1-19.
38. Torchilin, VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 4:2, pp. 145-160.
39. Toro, A. and Grunebaum, E. (2006) TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest, 116:10, pp. 2717-2726.
40. Trehin, R. and Merkle, HP (2004) Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur J Pharm Biopharm, 58:2, pp. 209-223.
41. Vives, E. (2005) Present and future of cell-penetrating peptide mediated delivery systems: Is the Trojan horse too wild to go only to Troy?. J Control Release, 109:1, pp. 77-85.
42. Wadia, JS and Dowdy, SF (2003) Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci, 4:2, pp. 97-104.
43. Wust, P. and Hildebrandt, B. (2002) Hyperthermia in combined treatment of cancer. Lancet Oncol, 3:8, pp. 487-497.
44. Wu, SP and Fu, AL (2006) A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase. Biochem Biophys Res Commun, 346:1, pp. 1-6.
45. Yoon, HY and Lee, SH (2002) TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells. Neurochem Int, 41:1, pp. 37-42.